Lluis F.
- Country
- Spain
- Department
- Urology
Research Overview
Data & Insights
Has run more than one trial at 0 of 119 partner sites.
Specializations
Prostate Cancer
The investigator concentrates on advanced disease states within the prostate gland, emphasizing therapeutic strategies for resistant and hormone‑driven forms.
- metastatic castration‑resistant prostate cancer
- hormone‑sensitive prostate cancer
- high‑risk localized prostate cancer
- PSA recurrence after definitive therapy
Clinical programs evaluate novel androgen‑axis inhibitors and combination regimens to improve survival outcomes.
Bladder & Urothelial Carcinoma
Research activities address both invasive and non‑invasive urothelial malignancies of the bladder and upper urinary tract.
- muscle‑invasive bladder cancer
- non‑muscle invasive bladder cancer
- BCG‑unresponsive disease
- upper tract urothelial carcinoma
Trials explore antibody‑drug conjugates, checkpoint blockade, and bladder‑preserving approaches.
Renal Cell Carcinoma
Focus is placed on clear‑cell and non‑clear‑cell subtypes, targeting intermediate to poor‑risk disease phenotypes.
- clear cell renal cell carcinoma
- non‑clear cell renal cell carcinoma
- intermediate‑risk renal cell carcinoma
- poor‑risk renal cell carcinoma
Investigations incorporate targeted kinase inhibitors and immune checkpoint therapies to extend progression‑free survival.
Kidney Transplant & Antibody‑Mediated Rejection
The investigator studies immunologic complications after renal transplantation, with an emphasis on antibody‑driven injury.
- antibody‑mediated rejection
- delayed graft function
- highly sensitized recipients
- imlifidase‑facilitated desensitization
- graft failure‑free survival
Clinical protocols assess novel agents aimed at reducing allo‑immune activation and improving long‑term graft outcomes.
Chronic Kidney Disease & Nephrology
Broader nephrologic interests encompass glomerular diseases, progressive renal insufficiency, and metabolic liver‑kidney interactions.
- IgA nephropathy
- chronic kidney disease
- end‑stage renal disease
- renal fibrosis
- metabolic dysfunction‑associated steatohepatitis
Efforts integrate biomarker discovery and renal outcome measures to guide therapeutic innovation.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.